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The impact of bariatric surgery on depression appears to be positive during the early months (the so-
called "honeymoon period"), but depressive symptoms tend to increase 36 months post-intervention 
(1). Despite the high prevalence of depression and obesity, little is known about pharmacokinetic 
modification of psychotropic drugs in patients undergoing bariatric surgery. Briefly, the reduction of 
gastric volume leads to a decrease in gastric mixing, an increase in gastric pH and an increase in gastric 
emptying, affecting disintegration and dissolution of the oral medication. The reduction in intestine 
length after Roux-en-Y gastric bypass (RYGB) leads to a reduction in the absorptive surface area and 
modification of presystemic drug metabolism (2). Limited clinical data are available for psychotropic 
drugs and concern mostly antidepressants. Two single-dose cross-sectional pharmacokinetic studies 
with 100 mg of sertraline and 60 mg duloxetine found a significant decrease in the area under the 
plasma concentration time curve compared to the placebo group (3, 4). A case series of four patients 
found a 33% (4%–71%) decrease of serum escitalopram concentrations compared to preoperative 
values two weeks after RYGB surgery (5). Another case series of 12 subjects treated with selective 
serotonin reuptake inhibitors (SSRI) and serotonin-noradrenaline reuptake inhibitors (SNRI) showed a 
decreased area under the curve (AUC) between 36 to 80% in eight patients 1 month after RYGB 
intervention (6). 
We present here the case of a 24-year-old Caucasian woman with a history of class III obesity, type 2 
diabetes, non-alcoholic fatty liver disease and anxiety-depressive disorder previously been 
unsuccessfully treated with two SSRIs (sertraline and fluoxetine). Vortioxetine, a “multimodal serotonin 
modulator" acting as an SSRI and additionally on 5-HT1A, 5-HT1B, 5-HT3 and 5-HT7 receptors, was 
introduced with good clinical efficacy on mood symptoms. The latter has a bioavailability of 75%, 
maximum plasma concentration reached 7–11 hours post-dose and an elimination half-life between 59 
and 69 hours. It is metabolized extensively in the liver, mainly via cytochrome P450 enzyme (CYP) 2D6 
and, to a lesser extent, via CYP3A4, CYP2C19 and CYP2C9 into six inactive metabolites (7).  
Additionally, she was treated with metformin (1000 mg/d), liraglutide (1.8 mg/d) and biotin (10 mg/d).  
Following assessment by the bariatric multidisciplinary team, she was eligible for an RYGB intervention.  
During the preoperative period, two blood level measurements of vortioxetine at 200 and 126 days 
before the intervention were taken. All concentrations were determined in steady-state conditions (> 2 
weeks at stable dosage before analysis) and after maximum plasma concentration (> 7 hours between 
last drug intake and blood sampling). All analyses were run using a UPLC-MS/MS (Waters Corporation, 
Milford, MA USA) method used for routine purposes. Vortioxetine concentrations were 24 and 23 ng/mL, 
using a daily dosage of 10 mg/d (Table 1).  
She underwent a RYGB intervention without complications. Metformin, liraglutide and biotin treatments 
were stopped after the intervention. She continued to receive vortioxetine in liquid form at the same 
dosage of 10 mg per day during the first month. After this period, the liquid form was switched to tablets 
at the same dosage. Vortioxetine blood level measurements were performed at 91, 224 and 308 days 
postoperatively to evaluate possible malabsorption. Vortioxetine concentration dropped to 11 ng/mL 91 
days after the intervention, using the same dosage. Based on this result and with the aim of avoiding a 
depressive relapse, the daily dosage was increased to 20 mg/d. After this dosage augmentation, 
vortioxetine concentration increased to 24 ng/mL at day 224 and 27 ng/mL at day 308, values 
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comparable to the preoperative period. Additionally, a phenotyping test was completed at day 308. A 
low-dose phenotyping cocktail approach was used to assess in vivo activity of CYP1A2, CYP2B6, 
CYP2C9, CYP2C19, CYP2D6 and CYP3A4 (8). Metabolic ratios (Table1) indicates an intermediate 
metabolizer phenotype for CYP2D6 and a normal phenotype for CYP2C19, CPY2C9 and CYP3A4. 
The evolution of vortioxetine concentrations corrected by the daily dose (C/D) during the preoperative 
and postoperative periods is presented in Figure 1. As the time between the last drug intake and blood 
sampling ranges between 8 and 24 hours, an estimation of trough concentration at 24 hours was made 
using a mean half-life of 64 hours (C/D calculated 24 hours post-dose: dotted line in Figure 1). During 
the postoperative period, the mean of C/D values decreased by approximately 50% compared to the 
preoperative period, using either the uncorrected or 24-hour adjusted C/D. This is slightly higher than 
the 25%–46% decrease in escitalopram C/D 6 weeks after intervention, as reported in a prospective 
case series (5). Interestingly, the postoperative C/D ratio remained unchanged one year after 
intervention, suggesting a long-term absorption impairment. This is in contradiction with another 
prospective case series with various SSRIs and SNRIs which found a normalization of AUC/dose ratio 
after one year (6). However, two case-controlled studies investigating sertraline and duloxetine found a 
decrease of the AUC of approximately 60% compared with matched controls one year post-RYGB, also 
suggesting an impaired bioavailability during at least the first year (3, 4).  
Of note, preoperative C/D values ranged between 2 and 2.5, two-fold higher than the reported C/D in 
the literature (mean value 1.1), but these decreased to normal values in the postoperative period (9). 
As the phenotyping test indicated an intermediate metabolizer phenotype for CYP2D6, we may 
hypothesize that the high pre-operative C/D values were due to impaired metabolism, compensated by 
a decrease in absorption during the postoperative period. Normal activity for CYP3A4, CYP2C19 and 
CYP2C9 were also observed; however these are minor metabolic pathways and probably did not 
compensate for the intermediate activity of CYP2D6. Of note, no co-medication known to inhibit or 
induce CYP activity was found in the medical record files for the pre- and post-operative periods. 
Regarding the validity of a phenotyping test in post-RYGB conditions, a recent cohort study using the 
same methodology found no significant influence from this intervention (10). Over-compliance during 
the preoperative period may also be a reason for the high C/D ratio. However, due to the long half-life, 
this over-compliance should last for several weeks before each blood sample.  
Because mood symptoms are often changing during the first postoperative year, it is difficult to assess 
whether this is due to environmental/psychological factors rather than malabsorption of antidepressive 
treatment. For this reason, routine use of therapeutic drug monitoring (TDM) is a valuable tool to exclude 
mood relapses due to malabsorption. General recommendations regarding oral pharmacotherapy after 
bariatric surgery are often based on a modification of the formulation: orally dispersible, liquid, crushing 
pills if applicable, increasing / dividing the daily dose, or changing the psychotropic drug (2). Briefly, a 
psychopharmacotherapy adaptation should be initiated during the preoperative period based on a 
determination of the basal psychotropic drug concentration (if applicable) and to evaluate the possibility 
of switching to a liquid oral dosage or sublingual melting forms. Shortly after surgery, clinicians should 
be aware of the presence of withdrawal symptoms and plasma levels should be obtained to exclude 
malabsorption. In case of malabsorption, daily dosage increase, switching to liquid oral dosage forms, 
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crushing tablets (according to the package insert) or dividing the daily dosage into several daily drug 
intakes are strategies that can easily be implemented. All these strategies should be followed by TDM 
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Table 1: Clinical parameters before and after bariatric intervention. 
 
Parameter   Preoperatively (days)   Postoperatively (days) 
  200 126   91 224 308 
Therapeutic drug monitoring information        
Dose, mg/d  10 10  10 20 20 
Time between last drug intake and blood sampling, h#  24 10  8 12 9 
Serum concentration, ng/mL  24 23  11 24 27 
Calculated serum concentration 24 hours post-dose, 
ng/mL  24 20  9 21 23 
Clinical information        
Weight, kg  125 125  109 94 90 
BMI, kg/m2  43.8 43.8  38.2 32.9 21.5 
Weight loss, %     13 25 28 
Phenotyping results (CYP activity)        
CYP 1A2       Slow 
CYP 2B6       Normal 
CYP 2C9       Normal 
CYP 2C19       Normal 
CYP 2D6       Intermediate 
CYP 3A4       Normal 









Figure 1: Concentration of vortioxetine corrected by the dose (C/D ratio) before (negative days) and 
after (positive days) bariatric surgery. The dotted line corresponds to the trough concentration 
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